candesartan has been researched along with Brain Ischemia in 44 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke." | 9.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) indicated that blood pressure-lowering treatment with candesartan in the acute phase of stroke has a negative effect on functional outcome at 6 months, measured by the modified Rankin scale." | 9.20 | Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015) |
| "The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg." | 9.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 9.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| " We have previously shown an enhanced VEGF-B expression in response to candesartan treatment after focal cerebral ischemia." | 7.88 | Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia. ( Eldahshan, W; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Soliman, S, 2018) |
| "We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia." | 7.81 | Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. ( Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015) |
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 7.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 7.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 7.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| "Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats." | 7.76 | Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. ( Culman, J; Hocher, B; Mueller, S; Muller, DN; Pfab, T; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A; Zhao, Y, 2010) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 7.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| " This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of neurotrophins." | 7.74 | Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. ( Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008) |
| "To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke." | 7.73 | Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006) |
| "Excessive superoxide production after cerebral ischemia is known to mediate neuronal injury." | 5.33 | Candesartan reduces superoxide production after global cerebral ischemia. ( Kinouchi, H; Mizoi, K; Oda, M; Omae, T; Shoji, H; Sugawara, T, 2005) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 5.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized controlled and placebo-controlled trial of candesartan within 30 h of ischaemic or haemorrhagic stroke." | 5.22 | Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2016) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke." | 5.20 | Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. ( Bath, PM; Berge, E; Jusufovic, M; Karlson, BW; Sandset, EC, 2015) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of blood pressure-lowering treatment with candesartan in acute stroke." | 5.20 | Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC; Sandset, PM, 2015) |
| "The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg." | 5.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) indicated that blood pressure-lowering treatment with candesartan in the acute phase of stroke has a negative effect on functional outcome at 6 months, measured by the modified Rankin scale." | 5.20 | Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 5.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| " We have previously shown an enhanced VEGF-B expression in response to candesartan treatment after focal cerebral ischemia." | 3.88 | Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia. ( Eldahshan, W; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Soliman, S, 2018) |
| "We have previously reported that angiotensin type 1 receptor (AT1R) blockade with candesartan exerts neurovascular protection after experimental cerebral ischemia." | 3.81 | Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats. ( Ergul, A; Fagan, SC; Fouda, AY; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Soliman, S, 2015) |
| "Candesartan has been reported to have a protective effect on cerebral ischemia in vivo and in human ischemic stroke." | 3.81 | Candesartan improves ischemia-induced impairment of the blood-brain barrier in vitro. ( Deli, MA; Hayashi, K; Hiu, T; Matsuo, T; Morofuji, Y; Nagata, I; Nakagawa, S; Niwa, M; So, G; Suyama, K; Tanaka, K, 2015) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 3.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 3.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "Head-to-head comparison suggests that treatment with aliskiren before and during cerebral ischemia is at least as effective as candesartan in double transgenic rats." | 3.76 | Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. ( Culman, J; Hocher, B; Mueller, S; Muller, DN; Pfab, T; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A; Zhao, Y, 2010) |
| "This work aims at studying the possible alteration of renal renin secretion after human ischemic stroke and correlating it to the post stroke neurological and renal function alterations using angiotensin II type 1(AT1) receptor blocker (ARB), candesartan, and beta 1 adrenoreceptor blocker atenolol, which inhibits renin secretion, in Wistar rats subjected to middle cerebral artery occlusion." | 3.76 | Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke. ( Abbas, AM; Boshra, V; El Aal, IA; Elkhateeb, M; Saad, MA, 2010) |
| " In this study, we investigated the effect of postischemic treatment using the angiotensin II type 1 receptor blocker, candesartan, on brain damage in focal cerebral ischemia." | 3.75 | Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. ( Kitagawa, K; Okazaki, S; Omura-Matsuoka, E; Oyama, N; Sakoda, S; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2009) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 3.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| " This study aimed to compare potential neuroprotective effects of systemic pretreatment with the angiotensin receptor blocker, candesartan, and the angiotensin-converting enzyme (ACE)-inhibitor, ramipril, in normotensive Wistar rats after focal cerebral ischemia, with special emphasis on the regulation of neurotrophins." | 3.74 | Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. ( Krikov, M; Müller, S; Thone-Reineke, C; Unger, T; Villringer, A, 2008) |
| "To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke." | 3.73 | Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006) |
| "Focal cerebral ischemia in the rat upregulated the contractile responses to angiotensin II in the ipsilateral MCA, and this contraction was mediated by AT1 receptors." | 3.72 | Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. ( Edvinsson, L; Stenman, E, 2004) |
| "Candesartan was the most effective angiotensin receptor blocker (ARB) in crossing the blood-brain barrier." | 2.42 | Inhibiting angiotensin receptors in the brain: possible therapeutic implications. ( Unger, T, 2003) |
| "Protection against acute cerebral ischemia induced by AT1 blockade for 5 days is blood pressure independent and mediated by both AT2 and AT4 angiotensin receptors." | 1.35 | Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. ( Achard, JM; Bureau, A; Faure, S; Fournier, A; Javellaud, J; Oudart, N, 2008) |
| "However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke." | 1.35 | Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. ( Katovich, MJ; Mecca, AP; O'Connor, TE; Sumners, C, 2009) |
| "Transient middle cerebral artery occlusion was induced in male Wistar rats by the intraluminal filament technique for 2 h followed by recirculation." | 1.34 | Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat. ( Edvinsson, L; Henriksson, M; Jamali, R; Maddahi, A; Stenman, E, 2007) |
| "Excessive superoxide production after cerebral ischemia is known to mediate neuronal injury." | 1.33 | Candesartan reduces superoxide production after global cerebral ischemia. ( Kinouchi, H; Mizoi, K; Oda, M; Omae, T; Shoji, H; Sugawara, T, 2005) |
| "pretreatment with candesartan, 0." | 1.32 | Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. ( Blume, A; Culman, J; Gohlke, P; Groth, W; Unger, T, 2003) |
| "Focal cerebral ischemia, induced by middle cerebral artery occlusion/reperfusion (MCAO), was conducted at 4 wk after STZ injection." | 1.32 | Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. ( Granger, DN; Ishikawa, M; Kusaka, G; Kusaka, I; Nanda, A; Tang, J; Zhang, JH; Zhou, C, 2004) |
| "Pretreatment with candesartan for 3 days or nicardipine for 28 days was ineffective." | 1.31 | Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. ( Bregonzio, C; Falcón-Neri, A; Ito, T; Saavedra, JM; Terrón, JA; Yamakawa, H, 2002) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 1.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| "Candesartan treatment normalised the lower part of the autoregulatory curve in SHR, and markedly decreased cerebral ischaemia as a consequence of middle cerebral artery occlusion with reperfusion." | 1.31 | Pre-treatment with candesartan protects from cerebral ischaemia. ( Ito, T; Nishimura, Y; Saavedra, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (56.82) | 29.6817 |
| 2010's | 19 (43.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Culman, J | 4 |
| Jacob, T | 1 |
| Schuster, SO | 1 |
| Brolund-Spaether, K | 1 |
| Brolund, L | 1 |
| Cascorbi, I | 1 |
| Zhao, Y | 3 |
| Gohlke, P | 3 |
| Ishrat, T | 3 |
| Soliman, S | 2 |
| Eldahshan, W | 2 |
| Pillai, B | 3 |
| Ergul, A | 6 |
| Fagan, SC | 6 |
| Barakat, W | 1 |
| Safwet, N | 1 |
| El-Maraghy, NN | 1 |
| Zakaria, MN | 1 |
| Fouda, AY | 2 |
| Kozak, A | 4 |
| Johnson, MH | 4 |
| Panahpour, H | 1 |
| Nekooeian, AA | 1 |
| Dehghani, GA | 1 |
| Jusufovic, M | 3 |
| Sandset, EC | 6 |
| Bath, PM | 5 |
| Karlson, BW | 1 |
| Berge, E | 6 |
| So, G | 1 |
| Nakagawa, S | 1 |
| Morofuji, Y | 1 |
| Hiu, T | 1 |
| Hayashi, K | 1 |
| Tanaka, K | 1 |
| Suyama, K | 1 |
| Deli, MA | 1 |
| Nagata, I | 1 |
| Matsuo, T | 1 |
| Niwa, M | 1 |
| Sandset, PM | 1 |
| Hornslien, AG | 2 |
| Igland, J | 1 |
| Terént, A | 2 |
| Boysen, G | 2 |
| Murray, GD | 2 |
| Wyller, TB | 1 |
| Alhusban, A | 1 |
| Waller, JL | 1 |
| Faure, S | 1 |
| Bureau, A | 1 |
| Oudart, N | 1 |
| Javellaud, J | 1 |
| Fournier, A | 2 |
| Achard, JM | 2 |
| El-Remessy, AB | 1 |
| Machado, LS | 1 |
| Elewa, HF | 2 |
| Abdelsaid, M | 1 |
| Wiley, DC | 1 |
| Omura-Matsuoka, E | 1 |
| Yagita, Y | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Oyama, N | 1 |
| Sugiyama, Y | 1 |
| Okazaki, S | 1 |
| Sakoda, S | 1 |
| Kitagawa, K | 1 |
| Mecca, AP | 1 |
| O'Connor, TE | 1 |
| Katovich, MJ | 1 |
| Sumners, C | 1 |
| Henriksson, M | 2 |
| Russell, D | 1 |
| Bodegard, J | 1 |
| Kjeldsen, S | 1 |
| Hasvold, P | 1 |
| Stålhammar, J | 1 |
| Levin, LÅ | 1 |
| Saad, MA | 1 |
| Abbas, AM | 1 |
| Boshra, V | 1 |
| Elkhateeb, M | 1 |
| El Aal, IA | 1 |
| Gaur, V | 1 |
| Kumar, A | 1 |
| Schmerbach, K | 1 |
| Pfab, T | 1 |
| Mueller, S | 1 |
| Villringer, A | 2 |
| Muller, DN | 1 |
| Hocher, B | 1 |
| Unger, T | 4 |
| Thoene-Reineke, C | 1 |
| Jatuzis, D | 1 |
| Kõrv, J | 1 |
| Lüders, S | 1 |
| Richter, PS | 1 |
| Roine, RO | 1 |
| Thijs, V | 1 |
| Fu, H | 1 |
| Hosomi, N | 1 |
| Pelisch, N | 1 |
| Nakano, D | 1 |
| Liu, G | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Masugata, H | 1 |
| Sueda, Y | 1 |
| Itano, T | 1 |
| Matsumoto, M | 1 |
| Nishiyama, A | 1 |
| Kohno, M | 1 |
| Rodriguez-Perez, AI | 1 |
| Dominguez-Meijide, A | 1 |
| Lanciego, JL | 1 |
| Guerra, MJ | 1 |
| Labandeira-Garcia, JL | 1 |
| Ito, T | 3 |
| Yamakawa, H | 1 |
| Bregonzio, C | 1 |
| Terrón, JA | 1 |
| Falcón-Neri, A | 1 |
| Saavedra, JM | 3 |
| Groth, W | 1 |
| Blume, A | 1 |
| Christensen, H | 1 |
| Stenman, E | 2 |
| Edvinsson, L | 2 |
| Ando, H | 1 |
| Zhou, J | 1 |
| Macova, M | 1 |
| Imboden, H | 1 |
| Kusaka, I | 1 |
| Kusaka, G | 1 |
| Zhou, C | 1 |
| Ishikawa, M | 1 |
| Nanda, A | 1 |
| Granger, DN | 1 |
| Zhang, JH | 1 |
| Tang, J | 1 |
| Sugawara, T | 1 |
| Kinouchi, H | 1 |
| Oda, M | 1 |
| Shoji, H | 1 |
| Omae, T | 1 |
| Mizoi, K | 1 |
| Lu, Q | 1 |
| Zhu, YZ | 1 |
| Wong, PT | 1 |
| Hill, WD | 1 |
| Pollock, DM | 1 |
| Xu, L | 1 |
| Hess, DC | 1 |
| Hamai, M | 1 |
| Iwai, M | 1 |
| Ide, A | 1 |
| Tomochika, H | 1 |
| Tomono, Y | 1 |
| Mogi, M | 1 |
| Horiuchi, M | 1 |
| Brdon, J | 1 |
| Kaiser, S | 1 |
| Hagemann, F | 1 |
| Ozacmak, VH | 1 |
| Sayan, H | 1 |
| Cetin, A | 1 |
| Akyildiz-Igdem, A | 1 |
| Jamali, R | 1 |
| Maddahi, A | 1 |
| Rojas, A | 1 |
| González, I | 1 |
| Figueroa, H | 1 |
| Hallevi, H | 1 |
| Hazan-Hallevi, I | 1 |
| Paran, E | 1 |
| Krikov, M | 1 |
| Thone-Reineke, C | 1 |
| Müller, S | 1 |
| Nishimura, Y | 2 |
| Dalmay, F | 1 |
| Mazouz, H | 1 |
| Allard, J | 1 |
| Pesteil, F | 1 |
| Saavedra, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Brain Ischemia
| Article | Year |
|---|---|
Inhibiting angiotensin receptors in the brain: possible therapeutic implications.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ben | 2003 |
6 trials available for candesartan and Brain Ischemia
| Article | Year |
|---|---|
Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2015 |
Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; D | 2015 |
Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; F | 2015 |
Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphen | 2015 |
Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2016 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
37 other studies available for candesartan and Brain Ischemia
| Article | Year |
|---|---|
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2017 |
Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Disease Models, Animal; Infarction, Mid | 2018 |
Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compounds | 2014 |
Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Disease Models, Animal; Male; Neuronal | 2015 |
Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Candesartan improves ischemia-induced impairment of the blood-brain barrier in vitro.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Barrier; Brain Ischemia; Cell Survival; Ele | 2015 |
Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.
Topics: Angiogenesis Inducing Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Benzim | 2017 |
Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2008 |
Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compoun | 2009 |
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2009 |
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2009 |
Health-care costs of losartan and candesartan in the primary treatment of hypertension.
Topics: Acute Coronary Syndrome; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor | 2010 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Bi | 2011 |
Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.
Topics: Amides; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzimidaz | 2010 |
Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2011 |
Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Brain I | 2013 |
Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |
Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2003 |
Hypertension in acute stroke.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; Humans; | 2003 |
Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2004 |
Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Biphenyl | 2004 |
Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2004 |
Candesartan reduces superoxide production after global cerebral ischemia.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; Dose-Response Relations | 2005 |
Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; B | 2005 |
Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Blood Pressu | 2006 |
Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pr | 2006 |
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Are | 2007 |
AT1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2007 |
Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2007 |
Re: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line, Transformed; Dipyridam | 2008 |
The ECV-304 cell-line: should it be used?
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line; Dipyridamole; Endothel | 2008 |
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Brain-Derived | 2008 |
Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
Non-AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; B | 2001 |
Pre-treatment with candesartan protects from cerebral ischaemia.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Occlusive Diseases; Benzimidazoles; Biphenyl Com | 2001 |